Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis-Reference-Cited by-同舟云学术

Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis

Published:2019-11-13 Issue:1 Volume:9 Page:160-169
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Chan Kelvin K. W.¹²³^ORCID,Guo Helen¹,Cheng Sierra²^ORCID,Beca Jaclyn M.³⁴,Redmond‐Misner Ruby⁴,Isaranuwatchai Wanrudee³⁴,Qiao Lucy¹,Earle Craig²⁵,Berry Scott R.²,Biagi James J.⁶,Welch Stephen⁷,Meyers Brandon M.⁸,Mittmann Nicole¹,Coburn Natalie²,Arias Jessica¹,Schwartz Deborah¹,Dai Wei F.¹,Gavura Scott¹,McLeod Robin¹,Kennedy Erin D.¹⁹^ORCID

Affiliation:

1. Cancer Care Ontario Toronto ON Canada

2. Sunnybrook Odette Cancer Centre University of Toronto Toronto ON Canada

3. Canadian Centre for Applied Research in Cancer Control Toronto ON Canada

4. Pharmacoeconomics Research Unit Cancer Care Ontario Toronto ON Canada

5. Ontario Institute for Cancer Research Toronto ON Canada

6. Cancer Centre of Southeastern Ontario Kingston ON Canada

7. London Regional Cancer Program London ON Canada

8. Hamilton Health Sciences Centre Hamilton ON Canada

9. Mount Sinai Hospital Toronto ON Canada

Publisher

Wiley